Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Phase 1/2 Recruiting 132 enrolled Shenyang Sunshine Pharmaceutical Co., LTD.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer pain. The study includes two stages: a single-arm, open-label, dose-escalation and dose-expansion Phase Ib followed by a randomized, double-blind, placebo-controlled Phase IIa.

Timeline

Start: 2024-03-27
Primary completion: 2025-12
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SSS40	Unknown	20 mg	Subcutaneous

Indications

No indication recorded.